All In Biotech

Free tool

FAERS Monitor: Lazcluze

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219008 or its brand name (Lazcluze, Lazertinib Mesylate). Reports on generic versions are filed under their own applications.

Reports

865

Serious

621

72% of reports

Hospitalization

211

Death reported

35

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash162
  • infusion related reaction96
  • paronychia69
  • off label use60
  • neuropathy peripheral53
  • fatigue46
  • diarrhoea41
  • nausea36
  • pruritus35
  • stomatitis32
  • dermatitis acneiform31
  • dyspnoea29
  • decreased appetite28
  • dizziness27
  • oedema peripheral27

Reports by year received

View as table
YearReports
202113
202221
202312
202493
2025330
2026396

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,294 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
paronychiaSignal69387.9308.725,832
dermatitis acneiformSignal31124.588.03,658
infusion related reactionSignal9635.329.23,167
neuropathy peripheralSignal5313.610.4606
stomatitisSignal3212.89.1338
rashSignal1629.07.91,174
oedema peripheralSignal275.43.793
decreased appetiteSignal282.92.034
pruritusSignal352.21.623
off label use601.71.316
diarrhoea411.51.18
fatigue461.41.16
dizziness271.30.92
dyspnoea291.20.91
nausea361.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.